Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease
Abstract Background Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | Clinical Epigenetics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13148-018-0505-0 |
id |
doaj-fd38b53e8df744ab9c03def9dba142b4 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tomasz Dziaman Daniel Gackowski Jolanta Guz Kinga Linowiecka Magdalena Bodnar Marta Starczak Ewelina Zarakowska Martyna Modrzejewska Anna Szpila Justyna Szpotan Maciej Gawronski Anna Labejszo Ariel Liebert Zbigniew Banaszkiewicz Maria Klopocka Marek Foksinski Andrzej Marszalek Ryszard Olinski |
spellingShingle |
Tomasz Dziaman Daniel Gackowski Jolanta Guz Kinga Linowiecka Magdalena Bodnar Marta Starczak Ewelina Zarakowska Martyna Modrzejewska Anna Szpila Justyna Szpotan Maciej Gawronski Anna Labejszo Ariel Liebert Zbigniew Banaszkiewicz Maria Klopocka Marek Foksinski Andrzej Marszalek Ryszard Olinski Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease Clinical Epigenetics DNA epigenetic modification Ten-eleven translocation protein Colon cancer Inflammatory bowel disease Adenoma Demethylation |
author_facet |
Tomasz Dziaman Daniel Gackowski Jolanta Guz Kinga Linowiecka Magdalena Bodnar Marta Starczak Ewelina Zarakowska Martyna Modrzejewska Anna Szpila Justyna Szpotan Maciej Gawronski Anna Labejszo Ariel Liebert Zbigniew Banaszkiewicz Maria Klopocka Marek Foksinski Andrzej Marszalek Ryszard Olinski |
author_sort |
Tomasz Dziaman |
title |
Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_short |
Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_full |
Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_fullStr |
Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_full_unstemmed |
Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
title_sort |
characteristic profiles of dna epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel disease |
publisher |
BMC |
series |
Clinical Epigenetics |
issn |
1868-7075 1868-7083 |
publishDate |
2018-05-01 |
description |
Abstract Background Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven translocation family (TETs 1, 2, 3). Decreased level of epigenetic DNA modifications in cancer tissue may be a consequence of reduced activity/expression of TET proteins. To determine the role of epigenetic DNA modifications in colon cancer development, we analyzed their levels in normal colon and various colonic pathologies. Moreover, we determined the expressions of TETs at mRNA and protein level. The study included material from patients with inflammatory bowel disease (IBD), benign polyps (AD), and colorectal cancer (CRC). The levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in examined tissues were determined by means of isotope-dilution automated online two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS). The expressions of TET mRNA were measured with RT-qPCR, and the expressions of TET proteins were determined immunohistochemically. Results IBD was characterized by the highest level of 8-oxodG among all analyzed tissues, as well as by a decrease in 5-hmdC and 5-mdC levels (at a midrange between normal colon and CRC). AD had the lowest levels of 5-hmdC and 5-mdC of all examined tissues and showed an increase in 8-oxodG and 5-(hydroxymethyl)-2′-deoxyuridine (5-hmdU) levels. CRC was characterized by lower levels of 5-hmdC and 5-mdC, the lowest level of 5-fdC among all analyzed tissues, and relatively high content of 5-cadC. The expression of TET1 mRNA in CRC and AD was significantly weaker than in IBD and normal colon. Furthermore, CRC and AD showed significantly lower levels of TET2 and AID mRNA than normal colonic tissue. Conclusions Our findings suggest that a complex relationship between aberrant pattern of DNA epigenetic modification and cancer development does not depend solely on the transcriptional status of TET proteins, but also on the characteristics of premalignant/malignant cells. This study showed for the first time that the examined colonic pathologies had their unique epigenetic marks, distinguishing them from each other, as well as from normal colonic tissue. A decrease in 5-fdC level may be a characteristic feature of largely undifferentiated cancer cells. |
topic |
DNA epigenetic modification Ten-eleven translocation protein Colon cancer Inflammatory bowel disease Adenoma Demethylation |
url |
http://link.springer.com/article/10.1186/s13148-018-0505-0 |
work_keys_str_mv |
AT tomaszdziaman characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT danielgackowski characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT jolantaguz characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT kingalinowiecka characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT magdalenabodnar characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT martastarczak characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT ewelinazarakowska characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT martynamodrzejewska characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT annaszpila characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT justynaszpotan characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT maciejgawronski characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT annalabejszo characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT arielliebert characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT zbigniewbanaszkiewicz characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT mariaklopocka characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT marekfoksinski characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT andrzejmarszalek characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease AT ryszardolinski characteristicprofilesofdnaepigeneticmodificationsincoloncanceranditspredisposingconditionsbenignadenomasandinflammatoryboweldisease |
_version_ |
1725378701225361408 |
spelling |
doaj-fd38b53e8df744ab9c03def9dba142b42020-11-25T00:17:38ZengBMCClinical Epigenetics1868-70751868-70832018-05-0110111110.1186/s13148-018-0505-0Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions—benign adenomas and inflammatory bowel diseaseTomasz Dziaman0Daniel Gackowski1Jolanta Guz2Kinga Linowiecka3Magdalena Bodnar4Marta Starczak5Ewelina Zarakowska6Martyna Modrzejewska7Anna Szpila8Justyna Szpotan9Maciej Gawronski10Anna Labejszo11Ariel Liebert12Zbigniew Banaszkiewicz13Maria Klopocka14Marek Foksinski15Andrzej Marszalek16Ryszard Olinski17Department of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Vascular Diseases and Internal Medicine, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Surgery, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Vascular Diseases and Internal Medicine, Faculty of Health Sciences, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Pathomorphology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunDepartment of Clinical Biochemistry, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in TorunAbstract Background Active demethylation of 5-methyl-2′-deoxycytidine (5-mdC) in DNA occurs by oxidation to 5-(hydroxymethyl)-2′-deoxycytidine (5-hmdC) and further oxidation to 5-formyl-2′-deoxycytidine (5-fdC) and 5-carboxy-2′-deoxycytidine (5-cadC), and is carried out by enzymes of the ten-eleven translocation family (TETs 1, 2, 3). Decreased level of epigenetic DNA modifications in cancer tissue may be a consequence of reduced activity/expression of TET proteins. To determine the role of epigenetic DNA modifications in colon cancer development, we analyzed their levels in normal colon and various colonic pathologies. Moreover, we determined the expressions of TETs at mRNA and protein level. The study included material from patients with inflammatory bowel disease (IBD), benign polyps (AD), and colorectal cancer (CRC). The levels of epigenetic DNA modifications and 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG) in examined tissues were determined by means of isotope-dilution automated online two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS/MS). The expressions of TET mRNA were measured with RT-qPCR, and the expressions of TET proteins were determined immunohistochemically. Results IBD was characterized by the highest level of 8-oxodG among all analyzed tissues, as well as by a decrease in 5-hmdC and 5-mdC levels (at a midrange between normal colon and CRC). AD had the lowest levels of 5-hmdC and 5-mdC of all examined tissues and showed an increase in 8-oxodG and 5-(hydroxymethyl)-2′-deoxyuridine (5-hmdU) levels. CRC was characterized by lower levels of 5-hmdC and 5-mdC, the lowest level of 5-fdC among all analyzed tissues, and relatively high content of 5-cadC. The expression of TET1 mRNA in CRC and AD was significantly weaker than in IBD and normal colon. Furthermore, CRC and AD showed significantly lower levels of TET2 and AID mRNA than normal colonic tissue. Conclusions Our findings suggest that a complex relationship between aberrant pattern of DNA epigenetic modification and cancer development does not depend solely on the transcriptional status of TET proteins, but also on the characteristics of premalignant/malignant cells. This study showed for the first time that the examined colonic pathologies had their unique epigenetic marks, distinguishing them from each other, as well as from normal colonic tissue. A decrease in 5-fdC level may be a characteristic feature of largely undifferentiated cancer cells.http://link.springer.com/article/10.1186/s13148-018-0505-0DNA epigenetic modificationTen-eleven translocation proteinColon cancerInflammatory bowel diseaseAdenomaDemethylation |